Less Ads, More Data, More Tools Register for FREE

Morgan Stanley reiterates 'buy' for FTSE 100, highlights 'defensive' qualities

Mon, 24th Jan 2022 12:13

(Sharecast News) - Analysts at Morgan Stanley sounded a 'bullish' note on the outlook for the FTSE 100, highlighting its greater 'defensive' properties relative to rivals, higher dividend yields versus global peers, exposure to energy and record low expectations for growth in the profits of its constituent companies.

On just over two-thirds of the occassions that global equities had fallen over the past two decades, the MSCI UK index had outperformed MSCI Europe.

Under the assumption that inflation-adjusted bond yields would rise to -0.1%, they estimated that MSCI UK was set to outperform by approximately 12%.

And changing hands at 12.6 times' earnings, London's top-flight index was the cheapest major index when compared with the last 10 years.

Furthermore, consensus forecasts for earnings per share growth for MSCI UK of less than 3% felt "very low" to them.

Regarding its dividend payouts, MSCI UK was trading on a dividend yield of 3.6%, which was 150 basis points more than for the MSCI Europe if the UK were excluded.

The UK also stood to benefit from rising oil prices, because 25% of UK profits came from the energy sector, they pointed out.

At the individual company level, they singled out eight large capitalisation 'overweight' rates stocks that had over 10% upside left to their target price and the best "bull-bear skew".

Those included AstraZeneca, Diageo, Shell, RELX, Lloyds, Prudential and Vodafone.

All told, they had a 'buy' recommendation for the FTSE 100, labelling the investment case "compelling".

Related Shares

More News
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an ora...

28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant sa...

27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.